Introduction {#S5}
============

High intake of dietary fibre is associated with reduced risk for type 2 diabetes mellitus (T2DM) and has been shown to improve glycaemic control in T2DM ([@R1]). These effects of fibre have been suggested to be due, at least in part, to its fermentation by colonic bacteria into the short-chain fatty acids (SCFA) acetate, propionate and butyrate, which are readily absorbed from the colonic lumen.

SCFA may improve glucose control by reducing serum FFA; High FFA concentrations induce peripheral and hepatic insulin resistance ([@R2],[@R3]), and contribute to oxidative stress and thus deteriorate pancreatic β-cell function as well as insulin sensitivity ([@R4]). Reductions of FFA have been demonstrated in animals after acetate injections ([@R5],[@R6]) and in humans after oral SCFA ingestion ([@R7]), rectal SCFA infusion ([@R8]) and dietary fibre consumption ([@R9],[@R10]). These effects were often, but not always, associated with reduced glycaemic responses.

Different dietary fibres are fermented into different types and amounts of SCFA ([@R11],[@R12]), therefore, may affect glycaemic responses differently. Two fermentable dietary-fibres of particular interest in this respect are resistant-starch (RS) and inulin (IN). Resistant-starch is an insoluble type of cereal fibre while IN is a soluble fibre that can be found in many types of plant foods. Resistant-starch has been shown to increase insulin sensitivity in short- and long-term consumption studies ([@R13]--[@R16]) however, the mechanism is not clear. Inulin has been shown to improve glycaemic control in animals ([@R17]--[@R20]), however, the results human studies have been equivocal ([@R10],[@R21],[@R22]).

The amount of SCFA produced in the colon also depends on the composition of the colonic microbiota. Obese mice harbour an increased abundance of Firmicutes and decreased Bacteroidetes than lean mice ([@R23]); it has been suggested that such a microbiota produces SCFA (energy) more efficiently, and may therefore contribute to weight gain ([@R24]). Human studies are limited but tend to show that faecal SCFA concentrations were significantly higher in obese than lean participants ([@R25]--[@R28]). Numerous studies have compared the faecal abundance of Firmicutes and Bacteroidetes in lean vs obese subjects but no consistent findings have emerged ([@R29]--[@R31]).

However, if obese humans produce SCFA more efficiently than lean humans, then excess SCFA production may contribute to weight gain and an increased risk for T2DM. On the other hand, excess SCFA production may lower FFA concentrations and improve glucose control, and therefore decrease risk for T2DM. Thus, our objective was to compare the effects of adding RS or IN to glucose tolerance test (75g glucose) on acute postprandial responses of SCFA, glucose, insulin and FFA in overweight vs. lean participants. We hypothesized that, in overweight relative to lean subjects, RS and IN would elicit higher postprandial SCFA responses and have less effect in reducing serum FFA and second-mealglucose and insulin responses.

Methods {#S6}
=======

Participants {#S7}
------------

Male and non-pregnant, non-lactating females aged 18--65 years with body mass index (BMI) ≥20 and ≤353kg/m^2^ were recruited from a pool of participants previously involved in similar studies. Participants were excluded for any of the following reasons: presence of diabetes, cardiovascular, bowel, kidney or liver disease; use of medications which affect blood glucose or insulin sensitivity (such as diuretics); any use of antibiotics, laxatives, pre/probiotics or other drugs known to influence gastrointestinal function in the 3 months before the study; smoking; following any unusual dietary practices (such as weight loss diet, Atkins diet, vegan diet); abnormal plasma blood glucose (≥7.0 mmol/L); or anemia. Eligible participants were then divided prospectively into two groups based on their BMI; 12 participants in the LN group (BMI\<25) and 13 participants in the OWO group (BMI≥25). All tests were conducted at the Glycemic Index Laboratories, Toronto. Ethical approval for the study was obtained from the Research Ethics Board, University of Toronto. Participants gave written informed consent to participate in the study.

Phase 1 {#S8}
-------

Participants completed questionnaires related to demographics, medical history, drug use, bowel habit and physical activity ([@R32],[@R33]). They were given instructions on how to record their dietary intake and asked to keep a 3-day diet record. Participants were also given a faecal collection kit which consisted of the Fisher brand commode specimen collection system (Fisher Scientific, Ottawa, ON) and plastic bags. On the third day of the diet record or the day after, participants collected a faecal sample. The completed 3-day diet record and the plastic bag containing the faecal sample was immediately placed on dry ice, and brought to the lab within 24h of being collected. The frozen faecal samples were stored at −20°C until they were processed.

Phase 2 {#S9}
-------

A week after completing phase 1, participants began phase 2; a cross-over randomized controlled-trial, in which participants came to the laboratory on 3 separate occasions, separated by a 1-week washout. On each study day, subjects arrived at 8:00am after fasting for 12h; after warming their forearms with a heating pad for 2--3min, a cannula was inserted into a forearm vein and kept clear with periodic saline flushes. After a fasting blood sample was drawn, participants consumed a test drink within 5min, and further blood samples were drawn at 0.5,1,1.5,2,3 and 4h after the start of the test drink. Immediately after the 4-h blood sample, a standard lunch was provided. Participants ate the lunch within 15min, and further blood samples were drawn at 4.5,5,5.5, and 6h. Participants remained seated and awake for the duration of the study. Breath samples were collected at hourly intervals for 6h for breath hydrogen and methane.

Test drinks {#S10}
-----------

Each subject consumed all 3 treatments in random order. The sequence of the test meals were randomly assigned to the subjects by the study coordinator by using Random Integer Subject Generator (<http://www.random.org>). The test drinks consisted of 75g glucose (GLU) (Glucose; Grain Process Enterprises Ltd, Scarborough, ON, Canada) or 75g glucose +24g Oliggo-Fiber Instant Inulin (Inulin; 90% dietary fibre, 10% free fructose, glucose and saccharose; Inulin; Cargill Inc., Wayzata, MN, USA) or 75g glucose +28g resistant starch (RS) (Nutriose® FM06, Roquette, France; total fibre content of 85%; 24g RS and 4.2g rapidly digestible starch;) dissolved in 300mL water on the morning of the study. The inulin dose of 24g was based on a previous study from our lab ([@R10]) and the dose of 28g RS was chosen so that the amount of fibre it contained equaled the dose of inulin.

Standard lunch {#S11}
--------------

The standard lunch consisted of a cheese and tomato sandwich, a drink of apple juice (200mL), a bottle of water (500mL), and two chocolate cookies (for more details see [supplementary information](#SD1){ref-type="supplementary-material"}).

Biochemistry {#S12}
------------

The faecal sample was weighed and homogenized in a 400 series masticator (IUL Instruments, S.A., Barcelona, Spain). Aliquots of faeces were then transferred to individual vials for determination of pH and SCFA. Faecal pH was measured using a pH meter, and faecal SCFA were analyzed by gas chromatography as previously described ([@R34]). DNA extraction and Ion Torrent V6 16S-rRNA gene sequencing were performed as described elsewhere ([@R35]). Compositional analysis of the data using Principle Component Biplots was done as described ([@R36]).

Blood for glucose, insulin, C-peptide and FFA was drawn into tubes containing spray-coated silica and a polymer gel for serum separation (BD Canada Inc., Oakville, ON). Blood for SCFA was drawn into serum tube with no additive and an uncoated interior (BD Canada Inc., Oakville, ON, Canada). Serum glucose was measured by a glucose oxidase method (YSI 2300 STAT Plus^™^, YSI Life Sciences Inc., Yellow Springs, OH, USA) (inter-assay CV \<2%), insulin and C-peptide using the ELISA immunoassay (80-INSHU-E01.1 and 80-CPTHU-E01.1, E10, Alpco Diagnostic, Salem, NH) (Insulin: Intra- and inter-assay CVs \<10% and \<17% respectively. Analytical sensitivity is 0.399μlU/ml. And C-peptide: intra- and inter-assay CVs \<5% and \<9%, respectively; analytical sensitivity 2.95pmol/L). Serum FFA was measure using enzymatic technique that used acyl-CoA oxidase (Wako NEFA-HR([@R2]), Wako Chemicals USA, Inc., Richmond, VA, USA). All blood samples were allowed to clot at room temperature for 30min, centrifuged at 3000rpm for 15min at 4°C, and the serum aliquoted and stored at −70°C before analysis. Serum SCFA were measured by gas chromatography after microfiltration and vacuum distillation as previously described ([@R37]).

Breath samples of methane and hydrogen were measured by gas chromatography (Quintron Microlyzer, Model SC, Milwaukee, WI, USA) as previously described ([@R37]).

Power Analysis -- see [supplementary information](#SD1){ref-type="supplementary-material"}.

Statistical analysis {#S13}
--------------------

The primary results are reported as means ± standard error of mean (SEM). For glucose, insulin and c-peptide, incremental areas under the curve (iAUC; subtracting area below the baseline) over 0--2h and 2--4h were calculated using the fasting concentration as the baseline. For FFA, iAUC from the nadir to 4h (iAUCmin4) was calculated using the minimum concentration achieved over the first 4h as the baseline. For glucose, insulin, c-peptide and FFA, total areas under the curve (tAUC) were calculated over the 4--6h periods using the trapezoidal method. For SCFA, tAUC were calculated over the 0--4 and 4--6h periods, and iAUC from the nadir to 6h (iAUCmin6) were calculated using the minimum concentration achieved over the first 4h as the baseline. All AUCs were calculated using a computer spreadsheet (Microsoft Office Excel 2007).

To examine for the main effects of groups and treatments, and their interactions, the mixed-effects (random-effects) model was used to account for the within-participant correlation, which was introduced by the cross-over design.

To investigate a possible relationship between serum FFA and SCFA and second-meal glucose responses, the difference in response between IN and Control and between RS and Control were calculated, and the differences in FFA and SCFA were correlated with the differences in glucose tAUC from 4--6h. Two-group t-tests (two sided) were performed to analyze differences in baseline data between the groups. Differences were considered statistically significant if p \< =0.05. Statistical analyses were conducted using IBM SPSS Statistics version 22 (SPSS Inc., Chicago, IL, USA) and Stata 13.0 (College Station, TX, USA).

Results {#S14}
=======

Lean participants were significantly younger than OWO but LN and OWO did not differ significantly with respect to sex and ethnicity ([Table 1](#T1){ref-type="table"}). Concentrations of faecal SCFA ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}) and fasting serum SCFA ([Table 1](#T1){ref-type="table"}) were not significantly different between the groups. However, after age adjustment, faecal propionate was significantly higher in the LN group compared to the OWO group ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). Faecal bacterial profiles at the level of phyla, revealed no differences in the relative abundance of the Firmicutes and Bacteroidetes or in their ratio between the LN and the OWO group ([Supplementary Figure 1,2](#SD1){ref-type="supplementary-material"}). OWO had significantly higher fasting insulin, total- and low-density lipoprotein-cholesterol and triglycerides than LN, but similar glucose, aspartate transaminase, C-reactive protein and high-density lipoprotein-cholesterol concentrations.

Lean had lower mean intakes of fat(g), protein(g), CHO(g) sugars(g) and total calories than the OWO group, but the differences were not significant ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}).

Serum acetate, propionate and butyrate concentrations began to increase 2 to 4h after IN and were significantly higher than GLU from 4 to 6h ([Figure 1](#F1){ref-type="fig"}); thus, both the incremental AUC and the total AUC of all 3 SCFA after IN were significantly greater than those after GLU ([Table 2](#T2){ref-type="table"}). By contrast, it took 5--6h for mean serum SCFA concentrations after RS to begin to exceed those after GLU; by 6h after RS the concentrations of all 3 SCFA were significantly greater those after GLU by paired t-test when uncorrected for multiple comparisons ([Figure 1](#F1){ref-type="fig"}), but the differences were small and there were no significant differences between RS and GLU in incremental or total AUC ([Table 2](#T2){ref-type="table"}). There were no significant differences in serum SCFA responses between LN and OWO subjects ([Table 4](#T4){ref-type="table"}).

Breath hydrogen 2h after IN was significantly greater than after GLU and increased rapidly to reach a peak concentration at 5h which was about 60ppm greater than that after GLU. Breath hydrogen after RS increased gradually to became significantly greater than GLU at 4h, reaching a peak concentration at 5h of approximately 10ppm ([Supplementary Figure 3](#SD1){ref-type="supplementary-material"}). There was no difference in breath hydrogen responses between LN and OWO subjects (not shown). There were 8 methane producers, and their mean breath methane concentration tended to fall throughout the day with no difference among treatments.

Glucose iAUC from 0--2h was significantly greater after IN than GLU but the difference between RS and GLU not significant. However, after the standard lunch, tAUC 4--6h was significantly less after RS than GLU but there was no difference between IN and GLU ([Figure 2](#F2){ref-type="fig"}, [Table 3](#T3){ref-type="table"}). There were no significant differences in glycaemic response between the LN and OWO groups ([Table 4](#T4){ref-type="table"}).

There was no difference among treatments in serum insulin or c-peptide responses between 0--2h; however, the mean iAUC from 2--4h was greater after RS compared to GLU, and the difference was significant for c-peptide. During the 4--6-h period, serum insulin and c-peptide responses after IN were similar to those after GLU, but, after RS, tAUC 4--6h for serum insulin and c-peptide were significantly less than those after GLU ([Figure 2](#F2){ref-type="fig"}, [Table 3](#T3){ref-type="table"}). Serum insulin and c-peptide responses between 0--2h and 4--6h were significantly greater in OWO compared to LN ([Table 4](#T4){ref-type="table"}) but the effects of IN and RS were similar in the 2 groups.

Serum FFA responses were similar after IN compared to GLU. However, over the 0--4h and 4--6h periods the total AUC for FFA was significantly less after RS than GLU, due to a significantly smaller rebound between the nadir and 4h ([Figure 2](#F2){ref-type="fig"}, [Table 3](#T3){ref-type="table"}). FFA responses in LN did not differ significantly from those in OWO ([Table 4](#T4){ref-type="table"}).

The interaction term was not significant for any of the outcomes (probably due to small sample size), therefore, the interaction term was dropped from the statistical model to save power for the main effects.

The changes in serum butyrate iAUC from minimum (nadir) to 6h elicited by IN were negatively related to the changes in glucose tAUC at 4--6h (p=0.055) ([Supplementary Table 3A](#SD1){ref-type="supplementary-material"}). The changes in serum FFA rise (minimum nadir to peak nadir) elicited by RS tend to negatively relate to glucose tAUC 4--6h (p=0.059)([Supplementary Table 3A](#SD1){ref-type="supplementary-material"}). The changes in acetate tAUC at 0--4h elicited by IN were negatively correlated to the changes in FFA rise (p=0.034)([Supplementary Table 3B](#SD1){ref-type="supplementary-material"}).

DISCUSSION {#S15}
==========

It has been suggested, on one hand that excess production of colonic SCFA is a cause of obesity but on the other that colonic fermentation of dietary fibre improves insulin sensitivity, and therefore reduces the risk for T2DM ([@R14],[@R15],[@R38]). Our results show no significant differences in postprandial SCFA responses between LN and OWO participants after acute fibre consumption. Moreover, unlike previous reports ([@R26],[@R34],[@R39]), no significant differences in faecal SCFA concentrations between LN and OWO participants were seen. This does not support the hypothesis that excess SCFA production is a cause of obesity. Our results also suggest that any effect of the colonic fermentation of dietary fibre on glycaemic responses is not due to SCFA *per-se*, since IN increased serum SCFA without reducing the second-meal glycaemic response, whereas RS reduced the second-meal glycaemic response without increasing serum SCFA.

Although both IN and RS are fermentable, only IN elicited a significant increase in SCFA. The earlier elevation of acetate after IN compared to RS could reflect faster gastric emptying (which may also explain the increased glucose concentrations we saw after the IN breakfast), a more rapid transit of IN than RS through the small intestine, and more rapid and more proximal fermentation of IN than RS in the large intestine ([@R40]). To our knowledge, no acute human studies have compared the fermentation of IN and RS. However, 12h fermentation of faecal inocula from humans ([@R41]) showed that RS and IN produced similar amounts of total SCFA, with increased butyrate production from IN. Therefore, a study period longer than 6h may be required to detect rises in serum SCFA after RS.

In this study, the lower glucose response after RS at 4--6h compared to control, together with the reduced insulin and c-peptide responses, are consistent with other studies showing that RS treatment improves insulin sensitivity ([@R13],[@R15],[@R42],[@R43]). This reduced glycaemic response is likely not related to SCFA (as there was no significant increase in SCFA after RS), but rather to the reduced FFA rebound. The acute reduction in FFA could have been explained by the presence of a larger than expected amount of available, but slowly digested starch in the RS ingredient used, since both prolonged carbohydrate absorption ([@R44]) and an increase in the amount of carbohydrate absorbed ([@R3]) have been shown to reduce postprandial FFA rebound. The presence of enough additional available carbohydrate in the RS test meal compared to the control to reduce FFA at 3 and 4 hours might be expected to increase serum glucose and insulin concentrations at these times. By contrast, we found that, compared to control, RS only elicited a small but significant increase in insulin at 3hr and a small non-significant increase in glucose at 3hr. However, these differences are quite consistent with those of a study showing that increasing the dose of glucose consumed from 75 to 100g was associated with only a small increase in serum glucose (\~0.4mmol/L) at 3h, a small reduction in glycose at 4h, small increases in insulin (\~50--70 pmol/L) at 3 and 4h, and large reductions in FFA (\>0.1 mEq/L) at both 3 and 4h ([@R45]).

The suggestion that the reduced FFA concentration accounted for the reduced second-meal glucose response is supported by the positive correlation between the FFA rise elicited by RS before lunch and glucose concentrations after lunch. Robertson et al. demonstrated that supplementation of 30 g/day of RS for 4wks in healthy subjects significantly improved insulin sensitivity, reduced subcutaneous abdominal adipose tissue FFA (but not systemic FFA) and increased serum SCFA concentrations ([@R14]). However, in two other studies in healthy subjects, though a beneficial effect of RS on insulin sensitivity was seen, SCFA and FFA were either not measured ([@R46]) or showed no significant change ([@R15]). In a 12wk study in T2DM humans, RS supplementation resulted in lower postprandial glucose concentrations, and a reduction in fasting and postprandial FFA. However, no effects on insulin sensitivity or on serum SCFA concentrations were seen ([@R42]). Thus, more human studies are needed to understand how RS reduce glycaemic responses

The inability of IN to elicit a significant reduction in postprandial FFA rebound, despite a large increase in serum SCFA concentrations, was unexpected and not consistent with the results of several previous studies from our laboratory ([@R10],[@R37]). The increased glucose response before lunch was also unexpected and inconsistent with our previous studies which showed that the glycaemic response after adding 24 g IN to either high-fructose corn syrup ([@R10]) or to 75g glucose ([@R47]) was virtually identical to that after the control. The inverse relation between butyrate (min-6h) and glycaemic responses at 4--6h may show that butyrate may has a role in reducing glucose ([@R48]), though its elevation might not be consistent and high enough to significantly reduce blood glucose. Though animal studies have shown a positive effect of the inulin-type fructans on glucose control ([@R17]--[@R19]), a systematic review in humans did not find a conclusive result ([@R21]), possibly due to the differences among studies in fructan types, doses, durations of studies, health status of the participants, and analytical methods. Further investigations are needed in order to determine whether inulin has any effect on glycaemic control.

Surprisingly, we found no significant differences in serum SCFA responses between LN and OWO groups. However, this do not rule out increased colonic SCFA production in OWO compared to LN participants, since if this was also accompanied by increased hepatic and peripheral SCFA clearance, postprandial serum SCFA responses could be similar in the 2 groups. Moreover, a modest difference in SCFA responses between OWO and LN could have been missed, as about 85 subjects per group would be required to detect, with statistical significance, the difference we actually observed. With our current sample size, and with 80% power, a significant difference would have been detected only if the OWO group had produced almost twice the amount of acetate after IN than the amount the LN group produced. However, the lack of differences between our groups in faecal SCFA concentrations (as opposed to previous human studies ([@R25]--[@R27])), in faecal bacterial phyla, and in habitual dietary intakes, may suggest that the group of OWO subjects we studied did not produce more SCFA than the LN subjects. Whether the similar faecal and serum SCFA responses in our groups were due to their similar relative abundance of Firmicutes and Bacteroides, due to other factors that were not explored in our study (i.e., genetic variations ([@R49])), or due to a small sample size, should be further explored.

It is concluded that IN and RS differ in their acute postprandial effects: IN is rapidly fermented in the colon eliciting prompt and large increases in breath hydrogen and serum SCFA concentrations, whereas RS is more slowly fermented with much smaller increases in breath hydrogen and serum SCFA for 6h after consumption. The results provide no evidence that acute elevations in SCFA *per se* influence glucose metabolism. In addition, the results do not support the hypothesis that overweight/obesity is associated with increased colonic SCFA production. However, a larger sample size would be needed to rule out a modest increase in SCFA production in obesity.
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![Serum short-chain fatty acid responses elicited by the test meals\
Values are means±SEM for n=25 subjects.\
\* Significant difference between Inulin and Glucose by related samples Wilcoxon signed rank test (p\<0.05).\
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###### 

Characteristics of study participants at screening

                                                          Whole group (n=25)   Lean (n=12)   Overweight/obese (n=13)   P value[\*](#TFN2){ref-type="table-fn"}
  ------------------------------------------------------- -------------------- ------------- ------------------------- -----------------------------------------
  Body Mass Index (kg/m^2)^                               27.5 ± 1.0           23.2 ± 0.4    31.5 ± 1.0                \<0.001
  Age (y)                                                 39.8 ± 2.8           33.4 ± 3.7    45.8 ± 3.5                0.025
  Ethnicity A:C:O (n)[\*\*](#TFN3){ref-type="table-fn"}   5:16:4               2:9:1         3:7:3                     0.494
  Sex (M:F) (n)                                           12:13                7:5           5:8                       0.320
  Blood Samples                                                                                                        
  Acetate (μmol/L)                                        36 ± 4               42 ± 6        32 ± 5                    0.230
  Propionate (μmol/L)                                     1.1 ± 0.5            1.2 ± 0.2     1.0 ± 0.1                 0.347
  Butyrate (μmol/L)                                       0.40 ± 0.04          0.39 ± 0.04   0.41 ± 0.06               0.756
  Fasting Glucose (mmol/L)                                4.87 ± 0.84          4.76 ± 0.12   4.98 ± 0.11               0.202
  Fasting Insulin (pmol/L)                                43.1 ± 5.0           25.7 ± 3.0    57.77 ± 6.5               \<0.001
  Hematocrit                                              0.40 ± 0.01          0.39 ± 0.01   0.40 ± 0.01               0.710
  AST (U/L)                                               22.4 ± 1.4           21.7 ± 1.44   23.0 ± 2.31               0.657
  CRP (mg/L)                                              3.3 ± 1.5            0.7 ± 0.2     5.7 ± 2.8                 0.098
  Total cholesterol (mmol/L)                              4.70 ± 0.22          4.23 ± 0.19   5.11 ± 0.35               0.046
  Triglycerides (mmol/L)                                  0.94 ± 0.10          0.68 ± 0.08   1.18 ± 0.15               0.009
  HDL cholesterol (mmol/L)                                1.47 ± 0.05          1.53 ± 0.09   1.41 ± 0.06               0.300
  LDL cholesterol (mmol/L)                                2.85 ± 0.18          2.46 ± 0.16   3.19 ± 0.28               0.038

Values are means ±SEM except for Ethnicity and sex which are number of subjects.

Significance of difference between Lean and Overweight/obese groups;

A=Asian; C=Caucasian; O=Other

###### 

Serum short chain fatty acid responses elicited by the test meals

  Variable                Time after treatment (h)   Glucose                                          Treatment                                         
  ----------------------- -------------------------- ------------------------------------------------ ------------------------------------------------- -------------
  Acetate (μmol×h/L)      tAUC 0--4 h                79.7 ± 7.6                                       **108.4 ± 12.4**[a](#TFN5){ref-type="table-fn"}   80.4 ± 8.1
  tAUC 4--6 h             41.9 ± 3.8                 **102 ± 11.9**[b](#TFN6){ref-type="table-fn"}    52.9 ± 4.2                                        
  iAUC min-6 h            24.4 ± 2.8                 **94.5 ± 13.1**[b](#TFN6){ref-type="table-fn"}   36.1 ± 3.8                                        
                                                                                                                                                        
  Propionate (μmol×h/L)   tAUC 0--4 h                3.98 ± 0.21                                      4.25 ± 0.29                                       4.05 ± 0.27
  tAUC 4--6 h             2.26 ± 0.11                **3.04 ± 0.24**[b](#TFN6){ref-type="table-fn"}   2.48 ± 0.17                                       
  iAUC min-6 h            1.01 ± 0.09                **1.71 ± 0.20**[b](#TFN6){ref-type="table-fn"}   1.09 ± 0.13                                       
                                                                                                                                                        
  Butyrate (μmol×h/L)     tAUC 0--4 h                1.4 ± 0.1                                        **1.67 ± 0.14**[a](#TFN5){ref-type="table-fn"}    1.49 ± 0.14
  tAUC 4--6 h             0.71 ± 0.05                **1.51 ± 0.16**[b](#TFN6){ref-type="table-fn"}   0.83 ± 0.06                                       
  iAUC min-6 h            0.27 ± 0.03                **1.11 ± 0.15**[b](#TFN6){ref-type="table-fn"}   0.40 ± 0.05                                       

Values are mean±SEM for n=25; iAUC, incremental area under the curve; tAUC, total area under the curve; min6, measured from nadir to 6h.

Significantly different from Glucose (p\<0.02).

Significantly different from Glucose (p\<0.001).

###### 

Serum glucose, insulin, C-peptide and free-fatty acid responses elicited by the test meals

                         Time after treatment (h)   Treatment                                                       
  ---------------------- -------------------------- -------------- ------------------------------------------------ ------------------------------------------------
  Glucose (mmol×h/L)     iAUC 0--2 h                3.73 ± 0.49    **4.60 ± 0.55**[a](#TFN8){ref-type="table-fn"}   3.93 ± 0.56
  iAUC 2--4 h            −1.13 ± 0.23               −0.89 ± 0.25   −0.66 ± 0.30                                     
  tAUC 4--6 h            11.6 ± 0.3                 11.5 ± 0.3     **10.9 ± 0.3**[b](#TFN9){ref-type="table-fn"}    
                                                                                                                    
  Insulin (pmol×h/L)     iAUC 0--2 h                111.0 ± 18.8   114.9 ± 21.0                                     106.8 ± 16.8
  iAUC 2--4 h            23.7 ± 7.2                 33.3 ± 11.6    34.0 ± 10.1                                      
  tAUC 4--6 h            77.8 ± 10.5                76.7 ± 9.2     **66.7 ± 8.9**[a](#TFN8){ref-type="table-fn"}    
                                                                                                                    
  C-peptide (pmol×h/L)   iAUC 0--2 h                2660 ± 238     2770 ± 212                                       2720 ± 203
  iAUC 2--4 h            857 ± 151                  1055 ± 179     **1290 ± 241**[b](#TFN9){ref-type="table-fn"}    
  tAUC 4--6 h            2632 ± 211                 2617 ± 188     **2444 ± 197**[a](#TFN8){ref-type="table-fn"}    
                                                                                                                    
  FFA (mEq×h/L)          tAUC 0--4 h                1.05 ± 0.07    1.06 ± 0.08                                      **0.94 ± 0.06**[a](#TFN8){ref-type="table-fn"}
  tAUC 4--6 h            0.53 ± 0.03                0.52 ± 0.03    **0.48 ± 0.03**[a](#TFN8){ref-type="table-fn"}   
  iAUC min4              0.21 ± 0.03                0.19 ± 0.03    **0.15 ± 0.03**[b](#TFN9){ref-type="table-fn"}   

Values are mean ± SEM for n=25; iAUC, incremental area under the curve; min4, measured from nadir to 4h; tAUC, total area under the curve.

Significantly different from Glucose (p\<0.03).

Significantly different from Glucose (p\<0.01).

###### 

The mean serum SCFA, glucose, insulin, C-peptide and free-fatty acid (FFA) responses elicited by the test meals of the 3 visits in lean vs. overweight and obese participants

  Variable                Time           Lean (n=12)    Overweight and obese (n=13)   P value[\*](#TFN11){ref-type="table-fn"}
  ----------------------- -------------- -------------- ----------------------------- ------------------------------------------
  Acetate (μmol×h/L)      iAUC min6      46.2 + 6.1     56.7 + 9                      0.319
  tAUC 0--6h              158.2 + 14     152.2 + 19.8   0.799                         
                                                                                      
  Propionate (μmol×h/L)   iAUC min6      1.3 + 0.2      1.2 + 0.2                     0.386
  tAUC 0--6h              6.9 + 0.5      6.5 + 0.5      0.254                         
                                                                                      
  Butyrate (μmol×h/L)     iAUC min6      0.5 + 0.1      0.6 + 0.1                     0.78
  tAUC 0--6h              2.3 + 0.1      2.7 + 0.3      0.617                         
                                                                                      
  Glucose (mmol×h/L)      iAUC 0--2h     3.3 ± 0.5      4.8 ± 0.8                     0.076
  iAUC 2--4h              −1.1 ± 0.2     −0.7 ± 0.4     0.663                         
  tAUC 4--6h              11.7 ± 0.4     11.0 ± 0.3     0.208                         
                                                                                      
  FFA (mEq×h/L)           tAUC 0--4h     0.97 ± 0.11    1.07 ± 0.08                   0.425
  tAUC 4--6h              0.45 ± 0.03    0.57 ± 0.04    **0.038**                     
  iAUC min4               0.19 ± 0.05    0.17 ± 0.03    0.699                         
                                                                                      
  Insulin (pmol×h/L)      iAUC 0--2h     65.5 ± 738     152.8 ± 30.6                  **0.005**
  iAUC 2--4h              16.1 ± 3.1     43.5 ± 16.5    0.166                         
  tAUC 4--6h              49.5 ± 5.3     96.2 ± 14.4    **0.002**                     
                                                                                      
  C-peptide (pmol×h/L)    iAUC 0--2h     2139 ± 138     3250 ± 324                    **0.001**
  iAUC 2--4h              698 ± 108.7    1410 ± 304.6   0.136                         
  tAUC 4--6h              2030 ± 133.5   3056 ± 291     **0.001**                     

Values are mean ± SEM;

, P value for the difference between the lean group to the overweight and obese group; FFA, free fatty acids; iAUC, incremental area under the curve; min4, measured from nadir to 4h; tAUC, total area under the curve
